Halozyme Therapeutics, Inc. (HALO)
107.79
+0.07
(+0.06%)
USD |
NASDAQ |
Sep 02, 10:40
Halozyme Therapeutics Cash from Operations (TTM) : 818.60M for June 30, 2026
Cash from Operations (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 818.60M |
| March 31, 2026 | 677.42M |
| December 31, 2025 | 651.56M |
| September 30, 2025 | 611.00M |
| June 30, 2025 | 547.78M |
| March 31, 2025 | 503.86M |
| December 31, 2024 | 479.06M |
| September 30, 2024 | 402.95M |
| June 30, 2024 | 419.99M |
| March 31, 2024 | 431.03M |
| December 31, 2023 | 388.57M |
| September 30, 2023 | 368.67M |
| June 30, 2023 | 305.89M |
| March 31, 2023 | 279.28M |
| December 31, 2022 | 240.11M |
| September 30, 2022 | 240.17M |
| June 30, 2022 | 292.28M |
| March 31, 2022 | 288.94M |
| December 31, 2021 | 299.44M |
| September 30, 2021 | 267.84M |
| June 30, 2021 | 152.19M |
| March 31, 2021 | 118.59M |
| December 31, 2020 | 55.45M |
| September 30, 2020 | -22.09M |
| June 30, 2020 | -57.76M |
| Date | Value |
|---|---|
| March 31, 2020 | -85.84M |
| December 31, 2019 | -85.42M |
| September 30, 2019 | -48.34M |
| June 30, 2019 | -37.68M |
| March 31, 2019 | -31.75M |
| December 31, 2018 | -49.50M |
| September 30, 2018 | 93.29M |
| June 30, 2018 | 132.47M |
| March 31, 2018 | 134.34M |
| December 31, 2017 | 134.05M |
| September 30, 2017 | -34.96M |
| June 30, 2017 | -63.97M |
| March 31, 2017 | -59.82M |
| December 31, 2016 | -50.38M |
| September 30, 2016 | -49.81M |
| June 30, 2016 | -58.05M |
| March 31, 2016 | -36.27M |
| December 31, 2015 | -37.08M |
| September 30, 2015 | -22.82M |
| June 30, 2015 | -19.02M |
| March 31, 2015 | -43.73M |
| December 31, 2014 | -47.52M |
| September 30, 2014 | -61.70M |
| June 30, 2014 | -60.93M |
| March 31, 2014 | -56.12M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (TTM) Benchmarks
| Incyte Corp. | 1.980B |
| AVITA Medical, Inc. | -24.71M |
| Neurocrine Biosciences, Inc. | 839.70M |
| Iovance Biotherapeutics, Inc. | -264.18M |
| Editas Medicine, Inc. | -119.86M |